.png)
.png)
Latest news from BIA
Scientist.com Partners with UK-based BioIndustry Association (BIA)
Global outsourcing leader Scientist.com to deliver Faster ScienceTM to BIA members throughout the UK SAN DIEGO & LONDON, DATE (BUSINESS WIRE) - Scientist.com, the world’s largest marketplace for outsourced scientific services, today announced a partnership with the BioIndustry Association (BIA), the UK’s national trade association for innovative bioscience enterprises. The partnership will allow BIA members to access the Scientist.com marketplace, connect with global experts and purchase custom research services required for drug R&D.
BioIndustry Association publishes new explainer documents on engineering biology and cell and gene therapy
The UK Bioindustry Association (BIA) today publishes two new explainer documents on engineering biology and cell and gene therapy.
UK biotech firms raise more than £1.5 billion so far this year exceeding the total raised in 2017
The UK BioIndustry Association (BIA) and Informa Pharma Intelligence have today released the Biotech Financing Update June - August 2018 that shows that UK biotech companies have already raised more than £1.5 billion in 2018, surpassing the 2017 annual total of £1.2 billion.
BIA and MHRA publish report ‘Collaborative Working in the UK, Driving Innovation Forward’ following their eighth annual joint conference
The UK BioIndustry Association (BIA) and the Medicines and Healthcare products Regulatory Agency (MHRA) brought together experts from across the life sciences sector to discuss some hot topics and important developments through a series of presentations and panel discussions.
Evonetix named Best Synthetic Biology Company at OBN Awards
CAMBRIDGE, UK, 12 October 2018 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to scalable and high-fidelity gene synthesis, has received the award for “Best Emerging Synthetic Biology Company” at the 10th Anniversary of the Oxford Bioscience Network (OBN) Awards, in recognition of the Company’s novel gene synthesis technology, and its potential to facilitate the rapidly growing field of synthetic biology.
Evonetix wins Best Emerging Synthetic Biology Company at the OBN Awards
SynbiCITE would like to congratulate Evonetix on winning ‘Best Emerging Synthetic Biology Company’ at the 10th Annual OBN Awards Ceremony last night. The award recognises the emerging UK industrial or synthetic biology company that demonstrates the most promise. Entrants were assessed on capital raised, level of innovation and their contribution to the bioeconomy.
Stratagem IPM awarded gold for Best Employers in Eastern Region
This year for the first time, Stratagem employees took part in the Best Employers Eastern Region employee engagement survey. Over 140 Companies took part with replies from 15,000 employees. Stratagem IPM Ltd were very proud to be recognised as being amongst the best employers in the Eastern region and have earned this recognition through exceptional results in the Best Employers Eastern Region survey, rated on a host of factors by those who know best – our own employees.
LifeArc appoints new Head of IP
LifeArc, a leading UK medical research charity, is delighted to announce the appointment of Diana Sternfeld as its new Head of Intellectual Property (IP), effective 12th November 2018. Diana joins LifeArc from her partnership at Fieldfisher LLP and brings a wealth of life sciences experience, supporting and managing the IP needs of the biopharmaceutical industry.
Life Sciences Industrial Strategy & Sector Deal Newsletter | October 2018
Welcome to the October edition of the Life Sciences Industrial Strategy & Sector Deal Newsletter. Here you will find an update on how we are progressing with the implementation of phase 1 of the Life Sciences Sector Deal as well as our upcoming priorities and engagement opportunities.
CEO Update | Monday 15 October 2018
We’re at the beginning of a key week for the BIA as voting closes for our Board elections, and Thursday sees our flagship conference, the Bioscience Forum, along with our AGM and Autumn reception.
Video of the week | The immortal cells of Henrietta Lacks
In order to test medicines, study disease and unravel the workings of human cells, scientists need material to work with. To produce results which are consistent, scientists need the cells they work with to stay same each generation - in other words, they must all be clones. Cells harvested from a tumor belonging to a woman named Henrietta Lacks proved to be the key to this problem. These cells are able to produce faithful copies of themselves and have done so since 1951. Known as HeLa cells, they have been instrumental in producing everything from over-the-counter drugs, to unlocking the secrets of human DNA.
Guest Blog | RPC LLP | Risk management and regulation - an opportunity for life sciences innovators?
Compliance, regulation and red tape can be burdensome for manufacturers, but should they be viewed more positively? Risk management has the potential to add value and longevity to a product – and to offer an opportunity for growth. Here are reasons why investing in risk management should be a guiding principle for the entire product development cycle, from the initial concept right through to marketing and post-market surveillance:
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
